What is Achondroplasty Treatment Drug Market?
Achondroplasty treatment drug is used for the treatment of Achondroplasia, which is a rare genetic bone disorder. It causes the strong, flexible tissue called cartilage to not be made into bone as normal. The FGFR3 gene provides fibroblast growth factor receptor 3 which is used in converting cartilage to bone. FGFR3 is only one gene associated with achondroplasia. But still, no specific treatment is available for achondroplasia. There are so much research and development happening to cure achondroplasia. Moreover, growth hormone therapy is one of the treatments for achondroplasia for only a short duration of time. Increasing demand from parents who having achondroplasia boosting the demand for achondroplasia treatment drug market in the forecast period.
The market study is being classified by Type (Lipase Inhibitor, Appetite Suppresants and Human Growth Hormone), by Application (Hospital, Clinic and Others) and major geographies with country level break-up.
Ascendis Pharma A/S (Denmark), BioMarin Pharmaceutical Inc (United States), Ribomic Inc (Japan), Ultragenyx Pharmaceutical Inc (United States), BridgeBio Pharma, Inc. (United States) and Pfizer Inc. (United States) are some of the key players profiled in the study.
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Achondroplasty Treatment Drug market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Achondroplasty Treatment Drug market by Type, Application and Region.
On the basis of geography, the market of Achondroplasty Treatment Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Incidences of Achondroplastic Dwarfism
- Rising Concern Towards Physical Characteristics
- Achondroplasia Diagnosed after Birth with a Physical Exam
- Lack of Awareness related to Treatment
- Increasing Demand from the Parents who already Having an Achondroplasia
- Growing Product Development in Treatment of Achondroplasia by Various Manufacturers
- After Treatment Chances of Causing Unexpected New Mutations
Market Leaders and some development strategies
On 2nd November 2020, BioMarin Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once-daily injection analog of C-type Natriuretic Peptide (CNP) for children with achondroplasia, the most common form of disproportionate short stature in humans. This acceptance by the FDA marks the first marketing application accepted for treatment for achondroplasia in the United States.
In July 2019, Ascendis Pharma A/S utilizes its innovative TransCon technologies to address significant unmet medical needs, announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate the ACcomplisH Trial, a global phase 2 trial designed to evaluate the safety and efficacy of TransCon CNP in children with achondroplasia.
Key Target AudienceAchondroplasty Treatment Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase